PHIA - Koninklijke Philips N.V.
AMS
->
Healthcare
->
Medical Devices
Amsterdam,
Netherlands
Type: Equity
PHIA price evolution
PHIA
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $3953 | $3866 | ||
| Inventory | $3491 | $4095 | ||
| Total current assets | $9940 | $9686 | ||
| Long term investments | ||||
| Property, plant & equipment | $2483 | $2519 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $29406 | $29506 | ||
| Current liabilities | ||||
| Accounts payable | $1917 | $1646 | ||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $8287 | $8071 | ||
| Long term debt | $7035 | $7177 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $17378 | $17380 | ||
| Shareholders' equity | ||||
| Retained earnings | $5402 | $5348 | ||
| Other shareholder equity | $1268 | $1492 | ||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2303 | $3226 | ||
| Short term investments | $2 | |||
| Net receivables | $4256 | $4337 | $3967 | $4561 |
| Inventory | $3490 | $4049 | $3450 | $2993 |
| Total current assets | $9939 | $10259 | $10347 | $11227 |
| Long term investments | $1056 | $670 | ||
| Property, plant & equipment | $2483 | $2638 | $2699 | $2682 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $29405 | $30688 | $30961 | $27713 |
| Current liabilities | ||||
| Accounts payable | $1917 | $1968 | $1872 | $2119 |
| Deferred revenue | ||||
| Short long term debt | $202 | $886 | ||
| Total current liabilities | $8287 | $7934 | $7450 | $7735 |
| Long term debt | $6959 | $7270 | $6473 | $4757 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $17378 | $17439 | $16487 | $15812 |
| Shareholders' equity | ||||
| Retained earnings | $5402 | $8320 | $9344 | $7827 |
| Other shareholder equity | $1268 | $377 | $747 | -$340 |
| Total shareholder equity | $14438 | $11870 | ||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4471 | $4470 | ||
| Cost of revenue | ||||
| Gross Profit | $1933 | $1962 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1709 | $1741 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $32 | $42 | ||
| Interest expense | -$95 | -$105 | ||
| Net income | ||||
| Net income | $88 | $72 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $18169 | $17827 | $17156 | $19535 |
| Cost of revenue | $9988 | $10754 | ||
| Gross Profit | $8023 | $7232 | $7168 | $8781 |
| Operating activities | ||||
| Research & development | $1806 | $1783 | ||
| Selling, general & administrative | $4857 | $5107 | ||
| Total operating expenses | $7616 | $7372 | $16603 | $17653 |
| Operating income | $553 | $1882 | ||
| Income from continuing operations | ||||
| EBIT | $553 | $1882 | ||
| Income tax expense | -$73 | -$113 | -$103 | $284 |
| Interest expense | -$328 | -$154 | -$188 | -$160 |
| Net income | ||||
| Net income | -$466 | -$1608 | $3319 | $1187 |
| Income (for common shares) | $3319 | $1187 | ||
| (in millions $) | 31 Jan 2024 | 30 Jul 2023 | 31 Jan 2023 | 29 Sep 2022 |
|---|---|---|---|---|
| Net income | -$1330 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$636 | -$359 | -$1487 | |
| Financing activities | ||||
| Dividends paid | -$2 | -$1 | -$412 | |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$848 | -$168 | $500 | |
| Effect of exchange rate | -$79 | -$47 | $41 | |
| Change in cash and equivalents | $696 | -$214 | -$1131 | |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $3319 | $1187 | ||
| Operating activities | ||||
| Depreciation | $1268 | $938 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $5032 | $2689 | ||
| Investing activities | ||||
| Capital expenditures | -$397 | -$513 | ||
| Investments | -$66 | |||
| Total cash flows from investing | -$636 | -$1487 | -$3672 | -$1316 |
| Financing activities | ||||
| Dividends paid | -$2 | -$412 | -$482 | -$1 |
| Sale and purchase of stock | ||||
| Net borrowings | -$251 | $783 | ||
| Total cash flows from financing | -$848 | $500 | -$2347 | $483 |
| Effect of exchange rate | -$79 | $41 | $65 | -$55 |
| Change in cash and equivalents | $696 | -$1131 | -$923 | $1801 |
News
Fundamentals
| Market cap | $17.46B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 906.40M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.20 |
| Quick ratio | 0.78 |